Australia's largest stock trading and investment forum Australia's #1 stock forum

EYE

Click for more information

5.56%

19.0¢ nova eye medical limited

Norty norty The Analyst, they stated a 'material improvement in...

First 220 Last

Share
Profile

Follow
Tekvest

10,608 Posts.

1276

21/08/24

17:58

Post #: 75310936
Share

Originally posted by TheAnalyst007: ↑

Tough to tell, I'm not going to try to speculate on the numbers but they do say they expect a material improvement in the operating results compared to both FY23 and H1FY24. As such, I assume that H2 will be a fair bit better than -$5.5m.

In my initial post in this thread I provided the numbers for FY23 and FY24 EBITDA (excludes the impact of the impairment). Note I accidentally typed the incorrect years, so add a year to each of the numbers (oops). In FY23, the loss was -$5.9m in H1 and only -$2.7m in H2. Then in FY24 we got -$4.2m in H1. This could possibly suggest some seasonality with expenses, or that a large amount of expenditure in H1FY24 was one off in relation to the LCD troubles.

I'd be very happy with a similar result to H2 of FY23. We know that not having the impairment will have a big impact on its own, but I'd like to see the positive trend in EBITDA maintained as well.

I'm optimistic about it though and look forward to the result!

Expand

Norty norty The Analyst, they stated a 'material improvement in the glaucoma segment'. An Analyst would know to step as carefully around those words as the person who placed them on the PR piece knew to. As for 80% lift in sales - extremely norty indeed

EYE Price at posting: 23.0¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

What's causing the cost-of-living crisis, and how to navigate it

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

There are more pages in this discussion • 157 more messages in this thread...

First 220 Last

Add EYE (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change 0.010(5.56%)		Mkt cap ! $43.52M

Open	High	Low	Value	Volume
18.5¢	19.5¢	18.5¢	$12.62K	66.11K

Buyers (Bids)

No.	Vol.	Price($)
2	49388	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	63159	2

View Market Depth

No.	Vol.	Price($)
1	46494	0.190
4	117069	0.185
11	369640	0.180
7	163500	0.175
7	78000	0.170

Price($)	Vol.	No.
0.195	63159	2
0.200	109923	3
0.205	15050	1
0.210	40000	1
0.215	104291	3

Last trade - 12.20pm 18/10/2024 (20 minute delay)

EYE (ASX) Chart